We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




First Commercially Available Lab-Based Blood Test to Help Evaluate Concussion

By LabMedica International staff writers
Posted on 08 Mar 2023

A bump, blow, or whiplash to the head is the main cause of traumatic brain injury (TBI), which can lead to short- and long-term detrimental effects. More...

People affected by TBI may experience impaired memory, movement, sensation (such as hearing and vision), and emotional function (such as psychological symptoms and personality changes). The effects of TBI can last for a few days post-injury or become permanent. For a long time, the process for standard concussion evaluation has remained the same, where the physician relies on subjective Glasgow Coma Scale assessments and CT scans to detect brain tissue damage or lesions. Now, the first commercially available laboratory TBI blood test in the U.S. helps doctors evaluate patients with concussion by ruling out the need for a CT scan.

Abbott Diagnostics (Lake Bluff, IL, USA) has received U.S. Food and Drug Administration clearance for the first commercially available laboratory TBI blood test, making it widely available to hospitals in the U.S. The Alinity i TBI test measures complementary biomarkers in blood plasma and serum - Ubiquitin C-terminal Hydrolase L1 (UCH-L1) and Glial Fibrillary Acidic Protein (GFAP), that, in elevated concentrations, are tightly correlated to brain injury. It provides test results with 96.7% sensitivity and 99.4% negative predictive value. By testing for these two biomarkers immediately after an injury, health care providers can decide on the appropriate next steps and devise a treatment plan for the patients. The test is for use to aid in the evaluation of patients, 18 years of age or older, presenting with suspected mild traumatic brain injury (Glasgow Coma Scale score 13-15) within 12 hours of injury, to assist in determining the need for a CT (computed tomography) scan of the head. The test had earlier received European Union clearance and has been available in markets outside the U.S. since 2021.

The test, which runs on Abbott's Alinity i laboratory instrument, will help clinicians quickly and objectively evaluate people with mild TBIs (concussions). A patient visiting the hospital within 12 hours of suspected mTBI can be administered the Alinity i test. The process involves obtaining a blood sample from the arm, sending it to the lab for preparation and running the test on the Alinity i instrument. The test results are usually available in 18 minutes, and can be shared with the relevant healthcare providers for immediate evaluation. Negative results on the test prevent additional CT scans and eliminate waiting time at the hospital, thus reducing the cost burden on the healthcare system and patients, as well as reducing time spent in the emergency department.

"People sometimes minimize a hit to the head, thinking it's no big deal. Others wonder if a visit to the doctor or emergency room for a possible concussion will provide them with meaningful answers or care," said Beth McQuiston, M.D., medical director in Abbott's diagnostics business. "Now that this test will be widely available in labs across the country, medical centers will be able to offer an objective blood test than can aid in concussion assessment. That's great news for both doctors and people who are trying to find out if they have suffered a traumatic brain injury."

Related Links:
Abbott Diagnostics


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
New
Clinical Chemistry System
P780
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: The 3D paper-based analytical device has shown high clinical accuracy for adult-onset immunodeficiency (Photo courtesy of National Taiwan University)

Paper-Based Device Accurately Detects Immune Defects in 10 Minutes

Patients with hidden immune defects are especially vulnerable to severe and persistent infections, often due to autoantibodies that block interferon-gamma (IFN-γ), a key molecule in immune defense.... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.